Mecasermin
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Using no specialized skill — this is a direct report-generation task with an explicit template; producing the deliverable per the given schema and evidence pack.
Mecasermin: From Unspecified Original Indication to Monosomy X
One-Sentence Summary
The original approved indication for Mecasermin is not documented in the available regulatory data source, and mechanism-of-action data is currently missing. The TxGNN model's top-ranked prediction is Monosomy X, but this signal is supported by 0 clinical trials and 0 publications, and the underlying rationale is an indirect analogy rather than a validated mechanistic link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in current data source |
| Predicted New Indication | Monosomy X |
| TxGNN Prediction Score | 99.59% |
| Evidence Level | L5 |
| Norway Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data for Mecasermin is not available, and no original indication is recorded in the current data source. This is flagged as a blocking data gap (missing TFDA/package-insert warnings and contraindications) and a high-severity gap (missing MOA), both of which limit any confident mechanistic assessment.
For the top-ranked prediction, Monosomy X (commonly associated with Turner syndrome), the model's own rationale states that this condition is often accompanied by partial GH/IGF-1 axis insufficiency and growth delay, so IGF-1 supplementation could theoretically offer growth benefit. However, this is explicitly noted as an indirect analogy — Turner syndrome is conventionally managed with growth hormone (GH), not mecasermin (recombinant IGF-1), and there is no direct mechanistic evidence chain linking mecasermin specifically to this condition. The prediction should be treated as a graph-derived signal rather than a substantiated hypothesis.
Notably, a lower-ranked candidate in this evidence pack — growth hormone insensitivity syndrome with immune dysregulation 2, autosomal dominant (rank 3, score 99.06%) — has a considerably stronger mechanistic basis: it falls within the family of GH-insensitivity/Laron-type syndromes, which is the pharmacological space mecasermin (rhIGF-1) is designed to address by bypassing a defective GH receptor pathway. This candidate has already advanced to decision stage S1 (Research Question), versus S0 (Hold) for Monosomy X, and may warrant closer review despite its lower TxGNN score.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Norway Market Information
Mecasermin currently holds no marketing authorizations in Norway (total licenses: 0; market status: Not Marketed). No product, dosage form, or approved indication data is available in the current data source.
Safety Considerations
Please refer to the package insert for safety information. (Package-insert warnings, contraindications, and drug-drug interaction data are currently unavailable and are flagged as a blocking data gap requiring TFDA label retrieval before any safety-stage evaluation can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (Monosomy X) has only Evidence Level L5 (model prediction only, no clinical trials or literature) and is based on an indirect mechanistic analogy rather than a validated pathway. Combined with the absence of Norway market authorization and a blocking gap in package-insert safety data, there is currently insufficient basis to advance beyond preliminary research.
To proceed, the following is needed:
- TFDA/package-insert warnings and contraindications (blocking gap, DG001)
- Confirmed mechanism-of-action documentation from DrugBank or equivalent source (DG002)
- Documentation of Mecasermin's original approved indication(s)
- Targeted literature/clinical trial search for the mechanistically stronger candidate (growth hormone insensitivity syndrome with immune dysregulation 2, autosomal dominant), given its closer alignment with mecasermin's known pharmacology
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.